← Leaderboards
Shehzad Basaria
Seattle Inst For Biomedical/Clinical Res
$7,488,405
Attributed
$13,600,060
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,600,060 · 10
By mechanism
R01$11,223,431 · 4
R21$1,436,238 · 3
K24$938,505 · 1
M01$1,886 · 2
Top collaborators
- Jose M. Garcia11 shared
- Robert R Edwards7 shared
- Egidio Del Fabbro5 shared
- Thomas Storer2 shared
- Grace Huang1 shared
Most similar at Seattle Inst For Biomedical/Clinical Res
Same institution · by research overlap
- Joseph Iaquinto$510,573
- Bruce Sangeorzan$2,758,345
- Sakeneh Zraika$11,163,287
- David G Cook$3,168,052
- Jeffrey J Iliff$5,850,997
Others in their field
Top investigators on “Testosterone”
- Peter J. Snyder · University Of Pennsylvania$39,424,875
- Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$32,216,741
- William S Kremen · University Of California Davis$21,636,730
- Susan E. Hankinson · University Of Massachusetts Amherst$19,337,166
- Clint Dart · Health Decisions, Inc.$17,090,158
- Johannes D Veldhuis · University Of Virginia Charlottesville$14,582,703
Research focus
TestosteroneReportingUnited StatesMalignant NeoplasmsAndrogensMaleHypogonadismPatient PopulationQuality Of LifeOlder MenComparative EfficacyRandomizedDiagnosisMuscle StrengthFatigueDouble-Blind MethodMoodsReduced Muscle StrengthPlacebosSerumPrevalencePituitary GlandPopulation BasedProstate
Grant awards (32)
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency$661,925
R01 · FY2025 · AG
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer$517,115
R01 · FY2025 · CA
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging$185,485
K24 · FY2025 · AG · contact PI
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer$631,770
R01 · FY2024 · CA
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging$186,802
K24 · FY2024 · AG · contact PI
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism$808,489
R01 · FY2023 · AG · contact PI
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency$673,710
R01 · FY2023 · AG
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging$189,122
K24 · FY2023 · AG · contact PI
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer$125,176
R01 · FY2023 · CA
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism$808,489
R01 · FY2022 · AG · contact PI
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer$643,552
R01 · FY2022 · CA
Exploring the Role of Testosterone as a Novel Anti-Nociceptive Agent in Women with Chronic Pain and Opioid Use$223,750
R21 · FY2022 · AG · contact PI
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging$192,294
K24 · FY2022 · AG · contact PI
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism$95,625
R01 · FY2022 · AG · contact PI
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism$713,004
R01 · FY2021 · AG · contact PI
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency$673,599
R01 · FY2021 · AG
Exploring the Role of Testosterone as a Novel Anti-Nociceptive Agent in Women with Chronic Pain and Opioid Use$268,500
R21 · FY2021 · AG
Preventing a Decline in Physical Function in Older Androgen-Deprived Men with Structured Exercise Training$230,274
R21 · FY2021 · AG · contact PI
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging$184,802
K24 · FY2021 · AG · contact PI
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism$752,769
R01 · FY2020 · AG · contact PI
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency$679,841
R01 · FY2020 · AG
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer$663,748
R01 · FY2020 · CA
Gaining Metabolic Insight in Older Men undergoing Androgen Deprivation Therapy for Prostate Cancer$416,443
R01 · FY2020 · CA · contact PI
Preventing a Decline in Physical Function in Older Androgen-Deprived Men with Structured Exercise Training$278,803
R21 · FY2020 · AG · contact PI
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer$720,928
R01 · FY2019 · CA
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency$708,543
R01 · FY2019 · AG
Gaining Metabolic Insight in Older Men undergoing Androgen Deprivation Therapy for Prostate Cancer$443,641
R01 · FY2019 · CA · contact PI
Gaining Metabolic Insight in Older Men undergoing Androgen Deprivation Therapy for Prostate Cancer$485,064
R01 · FY2018 · CA · contact PI
Hypogonadism and Pain Perception in Androgen-Deprived Men with Prostate Cancer$191,059
R21 · FY2014 · CA · contact PI
Hypogonadism and Pain Perception in Androgen-Deprived Men with Prostate Cancer$243,852
R21 · FY2013 · CA · contact PI
ISOFLAVONES IN PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY$1,201
M01 · FY2007 · RR · contact PI
ISOFLAVONES IN PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY$685
M01 · FY2006 · RR · contact PI